Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCPG9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,664
Award facts
- Contract value 100% obligated
- $38,664.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,664.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. This firm fixed-price delivery order, awarded on January 8, 2026, with an ultimate completion date of January 9, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was funded by the DLA and fulfilled under DMS Pharmaceutical Group's role as a critical pharmaceutical supplier within the federal supply chain.
This delivery order operates under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded in November 2025 with a completion date of December 31, 2036. The PPV-G GEN V program, part of a broader $30.3 billion acquisition strategy, enables the DLA to issue delivery orders for comprehensive pharmaceutical products to support recurring medical supply needs of Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established performance history supplying diverse pharmaceutical products—including oncology treatments, biologics, vaccines, and specialty pharmaceuticals—positions it as a key regional prime vendor contractor supporting military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCPG9?
SPE2DR26FCPG9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FCPG9 worth?
The government has obligated $38,664 on SPE2DR26FCPG9.
Is contract SPE2DR26FCPG9 an order under another contract?
Yes. SPE2DR26FCPG9 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPG9 competed?
The extent of competition for SPE2DR26FCPG9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award